Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Post-Essential Thrombocythemia Myelofibrosis: early-phase trial registry
6 of 10 indexed Post-Essential Thrombocythemia Myelofibrosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 6 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Post-Essential Thrombocythemia Myelofibrosis: 10 US clinical trials tracked, 6 recruiting.
Post-Essential Thrombocythemia Myelofibrosis is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is John Mascarenhas, running 2 of these trials.
Enrollment posture brief
Registry condition post-essential-thrombocythemia-myelofibrosis
OPEN 6 | RECR 60% | LATE 3 | EARLY 7 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
Post-Essential Thrombocythemia Myelofibrosis lists 6 open slots (60% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Post-Essential Thrombocythemia Myelofibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Post-Essential Thrombocythemia Myelofibrosis is recruiting above its size-band peers.
6 of 10 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Post-Essential Thrombocythemia Myelofibrosis research.
John Mascarenhas accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Post-Essential Thrombocythemia Myelofibrosis trials plan to enrol fewer than 100 people.
Median target enrolment is 84 among the 10 trials that report a genuine target (sentinel values excluded). 6 of those (60%) plan for fewer than 100 participants.
-
Post-Essential Thrombocythemia Myelofibrosis research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Merck Sharp & Dohme
NCT06351631
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum
NCT03165734
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine
NCT05320198
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Ajax Therapeutics
NCT06343805
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center
NCT06218628
Study of Canakinumab in Patients With Myelofibrosis
John Mascarenhas
NCT05467800
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Novartis Pharmaceuticals
NCT04603495
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Incyte Corporation
NCT04455841
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
NS Pharma
NCT01423851
MPN-RC 118 AVID200 in Myelofibrosis
John Mascarenhas
NCT03895112
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Post-Essential Thrombocythemia Myelofibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Post-Essential Thrombocythemia Myelofibrosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Post-Essential Thrombocythemia Myelofibrosis page
10 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Post-Essential Thrombocythemia Myelofibrosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- John Mascarenhas sponsors the most Post-Essential Thrombocythemia Myelofibrosis trials on record, review their full trial history before evaluating a specific study. See John Mascarenhas's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Post-Essential Thrombocythemia Myelofibrosis condition card totals 10 registered trials; most-linked intervention AVID200; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.